A new trading day began on Monday, with Iterum Therapeutics Plc (NASDAQ: ITRM) stock price down -4.27% from the previous day of trading, before settling in for the closing price of $1.17. ITRM’s price has ranged from $0.62 to $2.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -39.15% over the last five years. Meanwhile, its annual earnings per share averaged 67.16%. With a float of $21.95 million, this company’s outstanding shares have now reached $22.71 million.
The firm has a total of 14 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.99%, operating margin of -1460.11%, and the pretax margin is -1066.98%.
Iterum Therapeutics Plc (ITRM) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Iterum Therapeutics Plc is 3.33%, while institutional ownership is 1.47%. The most recent insider transaction that took place on Dec 22 ’23, was worth 35,000. In this transaction Director of this company bought 25,000 shares at a rate of $1.40, taking the stock ownership to the 113,754 shares. Before that another transaction happened on Dec 18 ’23, when Company’s Director bought 10,000 for $1.84, making the entire transaction worth $18,442. This insider now owns 88,754 shares in total.
Iterum Therapeutics Plc (ITRM) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.3 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.16% per share during the next fiscal year.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Here are Iterum Therapeutics Plc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Analysing the last 5-days average volume posted by the [Iterum Therapeutics Plc, ITRM], we can find that recorded value of 0.33 million was lower than the volume posted last year of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 89.30%. Additionally, its Average True Range was 0.09.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 33.84%, which indicates a significant decrease from 70.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.88% in the past 14 days, which was lower than the 78.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0993, while its 200-day Moving Average is $1.3829. Now, the first resistance to watch is $1.2167. This is followed by the second major resistance level at $1.3133. The third major resistance level sits at $1.3767. If the price goes on to break the first support level at $1.0567, it is likely to go to the next support level at $0.9933. Should the price break the second support level, the third support level stands at $0.8967.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
With a market capitalization of 25.44 million, the company has a total of 16,555K Shares Outstanding. Currently, annual sales are 0 K while annual income is -38,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -5,000 K.
